Dudediligence.

Cartesian Therapeutics, Inc

RNACNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$387,000Sep ’24−$836,000Dec ’24$1.1MMar ’25$298,000Jun ’25$452,000Sep ’25$947,000Dec ’25$78,000Mar ’26$0.00Jun ’26
Net income, by quarter
−$24.2MSep ’24−$10.3MDec ’24−$17.7MMar ’25$15.9MJun ’25−$35.9MSep ’25−$92.6MDec ’25−$39.2MMar ’26$15.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$85.1M$110.8M$26.0M$38.9M$2.8M
Operating income−$4.6M$14.5M−$86.4M−$43.9M−$143.4M
Net income−$25.7M$35.4M−$219.7M−$77.4M−$130.3M
Operating cash flow−$60.4M−$31.6M−$51.2M−$23.7M−$73.9M
Free cash flow−$61.5M−$32.8M−$51.4M−$32.8M−$79.4M
Cash$114.1M$106.4M$76.9M$212.6M$125.1M
Debtnone on filenone on filenone on filenone on file$0.00
Shares outstanding123.6M153.0M5.4M25.8M26.0M